◆ NeutralGRCE
Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026
GlobeNewswire Inc.·
Grace Therapeutics (GRCE), a late-stage biopharma company developing GTx-104 for aneurysmal subarachnoid hemorrhage, announced its participation in BIO-Europe 2026 and the Craig-Hallum 17th Annual Alpha Select Conference in November 2026. CEO Prashant Kohli will meet with industry representatives and investors at these events.
Read Full Article at GlobeNewswire Inc. →